Indian regulators OK Glenmark Generics spinoff; Simcere: Workers at new Chinese plant in criminal probe;

 @FiercePharma: Novartis faces lawsuit from female sales reps. Article | Follow @FiercePharma

> The Securities and Exchange Board of India has approved a planned, $142.3 million initial public offering of Glenmark Generics, a wholly-owned subsidiary of Glenmark Pharmaceuticals, sources tell the Economic TimesReport

> Biotechs cater to the most creative scientists. Report

> Simcere Pharmaceutical disclosed that employees at its recently acquired Jiangsu Yanshen vaccine producer are under criminal investigation for allegedly covering up manufacturing screw-ups that led to the release of substandard human rabies vaccine doses two years ago. Report

> Tufts: Regulatory affairs' rising workload needs attention ASAP. Report

> Hikma has inked a deal to take full control of its Algerian joint venture in a $18.5 million transaction designed to continue its expansion in the region. Report

> Merck KGaA, the German drugmaker that bought Millipore, will finish syndicating 1 billion euros ($1.3 billion) of loans this week in the first acquisition financing for a listed company this year. Report

> Monsanto says it has completed its purchase of the Chesterfield Village Research Center in Chesterfield, Mo., from Pfizer. Report

> Efforts to attract large foreign companies to take the place of AstraZeneca's massive site in Leicestershire, England, could be seriously hampered by a new tax on the rich, local business leaders said. Report

> The board of United Drug has appointed Chris Brinsmead, a former AstraZeneca U.K. executive, as a non-executive director of the company. Report

> Mylan Pharmaceuticals won the final FDA nod for its version of Braintree Laboratories' NuLytely laxative. Release

> Aurobindo Pharma got final FDA approval for five dosage strengths of its version of Wyeth's antidepressant drug Effexor. Report

Biotech News

 @FierceBiotech: Sanofi opens R&D center in China. Article | Follow @FierceBiotech

 @JohnCFierce: Tengion IPO on Friday prices at $5, closes at 5.02. High risk, no revenue not what investors are looking for these days. | Follow @JohnCFierce

> Vernalis CEO insists he's hunting for new drug deals. Story

> Jackson Lab plots new Florida genomics research center. Item

> Struggling Canadian biotechs urged to look south for cash. Article

> Javelin jilts Myriad in favor of Hospira's $141M takeover offer. Story

Biotech IT

> iPad hosts Nextrials platform. Report

> Cancer center evaluates EDC solutions, picks Medidata Rave. Story

> ClearTrial targets site, trial costs in product upgrade. Item

And Finally... A new one-off treatment that could potentially "switch off" rheumatoid arthritis is to be tested by British scientists. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.